Avacopan

Introduction Overview

Generic Name

avacopan

Brand Name

Tavneos

Dosage Form

capsules (10 mg)

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Avacopan, the active ingredient in Tavneos, is rapidly absorbed following oral administration. The drug is formulated as capsules intended to be taken twice daily with food, which enhances its bioavailability. Food intake is recommended to mitigate gastrointestinal side effects and optimize absorption rates. The pharmacokinetic profile from clinical trials indicates that avacopan achieves peak plasma concentrations at approximately 1 to 2 hours post-dose, demonstrating a favorable absorption profile in adult patients with ANCA-associated vasculitis. The adequate oral absorption supports its use as an oral therapy for chronic immunosuppressive treatment.

Distribution:
Once absorbed, avacopan demonstrates extensive distribution throughout the body with a moderate volume of distribution, allowing adequate tissue penetration, including sites of inflammation characteristic of ANCA-associated vasculitis. The drug exhibits high plasma protein binding (~99%), primarily to albumin, which limits free circulating drug but also prolongs systemic exposure. Distribution to target tissues such as the kidneys and blood vessel walls is crucial for its efficacy. The binding characteristics might influence drug-drug interactions especially with other highly protein-bound drugs.

Metabolism:
Avacopan is metabolized primarily via hepatic pathways involving the cytochrome P450 system, with CYP3A4 as a key isoenzyme mediating its biotransformation. This metabolic pathway renders it susceptible to interactions with CYP3A4 inhibitors and inducers, necessitating dose adjustments and caution when co-administering with such agents. Metabolism produces inactive metabolites eliminated through renal and hepatic routes. Understanding the metabolic pathway is essential for managing potential interactions and hepatic safety monitoring.

Elimination:
The elimination half-life of avacopan supports twice-daily dosing regimens, with clearance occurring through both renal and biliary excretion. Approximately equal proportions of the administered dose are eliminated via urine and feces mainly as metabolites, with minimal unchanged drug excreted. The pharmacokinetics are generally unaffected by mild to moderate renal impairment, though clinical caution is advised. Liver function impacts elimination, thus liver toxicity monitoring is strongly recommended during therapy. The elimination profile allows for steady plasma concentrations, contributing to long-term disease control.

Dosage Forms

Available Dosage Forms:
Tavneos is available exclusively as oral capsules containing 10 mg of the active ingredient avacopan. These capsules are designed for oral administration and should be swallowed whole without crushing, chewing, or opening to maintain drug stability and bioavailability.

Dosages for Adults and Adolescents:
The recommended dosage for adults with severe active ANCA-associated vasculitis (including granulomatosis with polyangiitis and microscopic polyangiitis) is 30 mg taken twice daily, administered as three 10 mg capsules per dose with food. Treatment should be continued as prescribed by a healthcare provider, and dose adjustments must be considered when used concomitantly with CYP3A4 modulators.

Specific Patient Populations:
Dose modification to 30 mg once daily is advised when Tavneos is co-administered with strong CYP3A4 enzyme inhibitors to prevent elevated plasma avacopan concentrations leading to increased toxicity risk. Data on pediatric dosing are currently unavailable, and safety in this population has not been established. Caution is warranted in patients with hepatic impairment, with monitoring and potential dose adjustments as clinically indicated. Use during pregnancy and lactation requires a thorough risk-benefit discussion, as safety data are insufficient.

Additional Clinical Guidelines:
Tavneos capsules must be taken with meals to ensure optimal absorption and to reduce gastrointestinal intolerance. Patients are instructed not to alter the physical integrity of the capsules to maintain therapeutic efficacy. Missed doses should be skipped without doubling the next dose. Overdose management involves supportive care and emergency interventions as needed.

Mechanism Of Action

Tavneos (avacopan) exerts its therapeutic effect as a highly selective antagonist of the complement 5a receptor (C5aR), a pivotal receptor involved in the complement cascade-mediated inflammatory response. The complement system is an integral component of innate immunity; however, in ANCA-associated vasculitis, its dysregulation leads to excessive activation, contributing to vascular inflammation and tissue damage. By binding selectively to C5aR on neutrophils and other immune cells, avacopan inhibits C5a-induced neutrophil chemotaxis, activation, and degranulation, thereby mitigating the inflammatory cascade that causes vessel wall inflammation.

At the cellular level, inhibition of C5aR prevents receptor-mediated signaling pathways responsible for recruitment and activation of neutrophils at sites of inflammation. This blockade reduces expression of adhesion molecules, reactive oxygen species generation, and release of pro-inflammatory cytokines, culminating in decreased endothelial injury and preservation of organ function. The specificity of avacopan for C5aR confers a targeted immunomodulatory effect, distinguishing it from broad immunosuppressants that compromise host defenses more globally.

Biochemically, avacopan’s antagonism of C5aR interrupts complement cascade amplification without directly inhibiting earlier components or opsonization functions, potentially allowing maintenance of baseline immune surveillance while curtailing pathogenic inflammation. This property supports its clinical utility in managing ANCA-associated vasculitis by reducing disease activity and relapse rates with a more favorable safety profile.

Clinical studies, such as the pivotal Phase III ADVOCATE trial, have demonstrated that avacopan combined with standard therapy significantly improves remission rates while enabling reduction or elimination of glucocorticoids, thereby minimizing steroid-associated adverse effects. Compared to conventional therapies like cyclophosphamide or rituximab, which deplete immune cells broadly, avacopan offers a novel mechanism that focuses on complement-mediated pathways, making it a valuable addition in the immunosuppressive armamentarium for vasculitis care.

Pharmacological Actions

Selective antagonism of complement 5a receptor (C5aR) to inhibit pathological complement activation.
Reduction of neutrophil chemotaxis and activation at sites of vascular inflammation.
Suppression of pro-inflammatory cytokine release and oxidative burst in immune cells.
Mitigation of endothelial injury and vascular inflammation characteristic of ANCA-associated vasculitis.
Facilitation of disease remission by modulating complement-mediated immune response.
Allowing reduction in glucocorticoid use and associated adverse effects.
Targeted immunomodulation without broad immunosuppression.
Improvement in renal and pulmonary outcomes by reducing small vessel inflammation.
Interruption of complement cascade amplification without affecting opsonization.
Pharmacodynamic effects that translate into decreased relapse rates in vasculitis.
Distinct mechanism compared to conventional cytotoxic or B-cell depleting agents.

Therapeutic Or Clinical Uses

Treatment of severe active ANCA-associated vasculitis including granulomatosis with polyangiitis (GPA).
Treatment of microscopic polyangiitis (MPA), a form of ANCA-associated vasculitis.
Adjunctive therapy combined with standard glucocorticoid regimens.
Reduction in risk of disease relapse and induction of remission in vasculitis patients.
Steroid-sparing agent to minimize glucocorticoid-related side effects.
Management of vascular inflammation affecting kidneys, lungs, and respiratory tract.
Treatment for adults diagnosed with ANCA-associated vasculitis requiring immunosuppressive therapy.
Therapy intended to preserve organ function by controlling immune-mediated vascular injury.
Use in patients intolerant or with contraindications to conventional broad immunosuppressants.
Improvement in patient quality of life by reducing flares and systemic inflammation.
Part of combination treatment protocols tailored to individualized immunomodulation.
Option in patients where long-term immunosuppression is warranted with focused complement inhibition.

Side Or Adverse Effects

Nausea occurring in approximately 39% of patients.
Headache reported in about 34% of treated individuals.
Elevated blood pressure (hypertension) in roughly 30% of patients.
Diarrhea experienced by approximately 25% of users.
Vomiting observed in about 25% of cases.
Rash or cutaneous reactions noted in 19% of patients.
Fatigue or tiredness affecting 17% of patients.
Abdominal or stomach pain reported in 11% of cases.
Dizziness experienced by roughly 11% of patients.
Increased blood creatinine levels indicating potential renal effects in 10%.
Paresthesias such as pins and needles or numbness in approximately 9%.
Serious hypersensitivity reactions including anaphylaxis or angioedema.
Potential for liver toxicity manifesting as jaundice, elevated liver enzymes.
Severe infections including opportunistic infections, requiring careful monitoring.
Possible neurological symptoms such as confusion or drowsiness if complications arise.

Precautions

Perform baseline liver function tests and periodic monitoring during therapy due to hepatotoxicity risk.
Use with caution in patients with pre-existing liver impairment or abnormal liver function tests.
Monitor blood pressure regularly as hypertension is a common adverse effect.
Assess renal function parameters periodically given potential creatinine level elevations.
Avoid use in patients with active infections; treat any infections before initiating therapy.
Exercise caution in patients with history of hepatitis B or C due to infection reactivation risk.
Advise patients not to discontinue therapy abruptly without consulting healthcare providers.
Educate patients on recognizing signs of liver dysfunction and severe infections.
Dose adjustments required when co-administered with strong CYP3A4 inhibitors or inducers.
Ensure capsules are taken whole with food to minimize gastrointestinal intolerance.
Consider pregnancy status and breastfeeding; data insufficient to confirm safety in these populations.
Advise on avoiding concomitant CYP3A4 enzyme inducers to prevent loss of efficacy.
Careful assessment before use in elderly patients due to comorbidities and polypharmacy.
Monitor for neurological symptoms or signs of allergic reactions during therapy.
Maintain updated medication list to avoid dangerous drug interactions.

Warnings

Risk of serious liver toxicity; monitor liver enzymes and discontinue if significant hepatic injury occurs.
Potential for serious infections due to immunosuppressive effects; promptly evaluate any febrile illness.
Hypersensitivity reactions including anaphylaxis reported; immediate medical attention required if symptoms occur.
Hypertension is a common adverse event; uncontrolled hypertension may worsen disease outcomes.
Avoid concomitant use with strong CYP3A4 inducers which may reduce avacopan plasma levels and efficacy.
Reduced avacopan dose recommended when used with strong CYP3A4 inhibitors to avoid toxicity.
Not established as safe or effective in pediatric patients; use restricted to adult populations.
Unknown effects during pregnancy and breastfeeding; use only if potential benefit outweighs risks.
Do not crush, chew, or open capsules to avoid altered drug delivery and adverse events.
Serious infections including opportunistic and severe infections require vigilant monitoring.
Caution advised in hepatic impairment due to altered metabolism and elimination.
May cause gastrointestinal disturbances including nausea and vomiting that may impact adherence.
Risk of increased blood creatinine necessitates kidney function monitoring.
Potential neurological adverse effects including dizziness and confusion.
Patients should be counseled on adherence to dosing schedule to maintain therapeutic benefit.

Contraindication

Known hypersensitivity or allergy to avacopan or any inactive capsule ingredients.
Active, severe infections where immunosuppression could worsen clinical course.
Significant hepatic impairment or decompensated liver disease due to metabolism concerns.
Concomitant use with strong CYP3A4 inducers contraindicated due to reduced efficacy.
Pregnancy unless benefits outweigh potential risks as safety is not established.
Breastfeeding unless healthcare provider approves given unknown breast milk excretion.
Patients with history of severe allergic reactions to similar immunosuppressive drugs.
Use in pediatric patients contraindicated due to lack of established safety and efficacy.
Known hypersensitivities to polyethylene glycol 4000 or Polyoxyl-40 hydrogenated castor oil.
Concurrent administration with medications that cause serious drug-drug interactions without monitoring.
Patients unable to adhere to twice-daily dosing or swallow capsules intact.
Individuals with poorly controlled hypertension prior to therapy initiation.
Contraindicated in patients with active hepatitis B or C unless appropriately managed.
Patients with severe immunodeficiency disorders where further suppression poses high risk.
Those with overlapping autoimmune conditions requiring alternative therapeutic strategies.

Drug Interactions

Strong CYP3A4 enzyme inducers (e.g., rifampin, carbamazepine) markedly reduce avacopan plasma levels – avoid co-administration.
Strong CYP3A4 enzyme inhibitors (e.g., ketoconazole, clarithromycin) increase avacopan levels; dosage reduction to once daily is required.
CYP3A4 substrates may require dose adjustment when co-administered with Tavneos due to altered metabolism.
Concomitant use with other immunosuppressants requires close monitoring for additive immunosuppression and infections.
Avoid medications that significantly affect hepatic metabolism pathways to prevent toxicity or loss of efficacy.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may exacerbate renal effects; monitor kidney function.
Avoid grapefruit or grapefruit juice which can inhibit CYP3A4 and increase avacopan concentrations.
Interaction with glucocorticoids is expected as Tavneos is used adjunctively; monitor cumulative immunosuppressive effects.
Concurrent use with other antihypertensive agents may require adjustment due to potential blood pressure changes.
Supplement use (e.g., herbal CYP3A4 modulators like St. John's Wort) may alter avacopan exposure.
Careful management needed when combined with anticoagulants due to bleeding risk in vasculitis patients.
Azole antifungals may significantly increase avacopan exposure; dose and treatment duration should be evaluated.
Strong inducers or inhibitors of P-glycoprotein may influence avacopan pharmacokinetics; monitor therapy closely.
Vaccinations during therapy should be managed carefully due to immunosuppressive effects.
Multiple drug-drug interactions warrant regular medication reconciliation to ensure safety.

Preparations Of The Drug

Tavneos capsules each containing 10 mg of avacopan as active ingredient.
Inactive ingredients include polyethylene glycol 4000 (PEG-4000) and Polyoxyl-40 hydrogenated castor oil to facilitate oral delivery.
Oral capsules designed for intact swallowing; not suitable for crushing or opening.
Packaged in specialty pharmacy controlled distribution due to the drug’s status and monitoring requirements.
Stored at room temperature between 20°C to 25°C (68°F to 77°F) to maintain drug stability.
Commercially available only through select specialty pharmacies with limited distribution.
Patient support services such as Tavneos Connect Program assist with access, insurance coverage, and financial assistance.
Provided with detailed prescribing information for healthcare professionals including dosing, monitoring, and safety data.
Includes educational materials for patients about proper administration and adherence.
Available only as branded Tavneos; no generic formulations approved presently.
Packaging typically includes blister packs or bottles with clear labeling to prevent dosing errors.
Supplied with prescribing physician forms such as the Tavneos Start Form for treatment initiation.
Formulation optimized for chronic immunosuppressive therapy with good oral bioavailability.
Not formulated for intravenous or alternate routes of administration.
Produced under stringent quality controls by ChemoCentryx, now part of Amgen biotechnology products.